More Approvals For Alpharma Tooth Gel

4 December 1995

Alpharma has received additional approvals to market Elyzol Dental Gel for the treatment of periodontal disease in Italy, Germany, Cyprus, Indonesia, Israel, Kuwait, Norway and the United Arab Emirates. The product has already been launched in several of these markets.

Alpharma plans to market the product in cooperation with strategic partners with experience in the dental health field in some of these countries. For example, in Italy the product is being marketed by Industria Chimica e Farmaceutica SpA, while in Germany the firm is actively pursuing a partnership arrangement and expects to launch Elyzol in the first quarter of 1996.

Company chief executive Einar Sissener said that Elyzol is a "change of behavior" product, with a new concept that needs to be introduced to dental specialists as well as patients, a process which will take time and money, and the most cost-effective way for the company to penetrate these new markets is cooperation with established specialists.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight